Adoption of Abiraterone and Enzalutamide by Urologists

To investigate the adoption of abiraterone and enzalutamide by urologists. Abiraterone and enzalutamide are oral therapies approved for the treatment of metastatic castration-resistant prostate cancer, a disease most commonly treated by medical oncologists.

Source: Urology - May 24, 2019 Category: Urology & Nephrology Authors: Megan E.V. Caram, Samuel R. Kaufman, Parth K. Modi, Lindsey Herrel, Mary Oerline, Ryan Ross, Ted A. Skolarus, Brent K. Hollenbeck, Vahakn Shahinian Source Type: research